These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 34258506

  • 1. A Prospective Open-Label Observational Study of a Buffered Soluble 70 mg Alendronate Effervescent Tablet on Upper Gastrointestinal Safety and Medication Errors: The GastroPASS Study.
    Minisola S, Vargas AP, Letizia Mauro G, Bonet Madurga F, Adami G, Black DM, Qizilbash N, Blanch-Rubió J.
    JBMR Plus; 2021 Jul; 5(7):e10510. PubMed ID: 34258506
    [Abstract] [Full Text] [Related]

  • 2. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.
    Turbí C, Herrero-Beaumont G, Acebes JC, Torrijos A, Graña J, Miguélez R, Sacristán J, Marín F.
    Clin Ther; 2004 Feb; 26(2):245-56. PubMed ID: 15038947
    [Abstract] [Full Text] [Related]

  • 3. A novel effervescent formulation of oral weekly alendronate (70 mg) improves persistence compared to alendronate tablets in post-menopausal women with osteoporosis.
    Giusti A, Bianchi G, Barone A, Black DM.
    Aging Clin Exp Res; 2021 Sep; 33(9):2529-2537. PubMed ID: 33449337
    [Abstract] [Full Text] [Related]

  • 4. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD, Faraawi RY, O'Mahony MF, Nayar A, Massaad R, Evans JK, Yacik C.
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [Abstract] [Full Text] [Related]

  • 5. The Effect of Effervescent and Buffered Alendronate Compared to Conventional Alendronate on Markers of Bone Turnover: A Randomized Non-inferiority Trial.
    Hikmet R, Harsløf T, Langdahl BL.
    Calcif Tissue Int; 2023 Nov; 113(5):532-539. PubMed ID: 37803182
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy.
    Hiligsmann M, Maggi S, Veronese N, Sartori L, Reginster JY.
    Osteoporos Int; 2021 Mar; 32(3):595-606. PubMed ID: 33443610
    [Abstract] [Full Text] [Related]

  • 7. Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease.
    Hooper M, Faustino A, Reid IR, Hosking D, Gilchrist NL, Selby P, Wu M, Salzmann G, West J, Leung A.
    Osteoporos Int; 2009 Jan; 20(1):141-50. PubMed ID: 18536953
    [Abstract] [Full Text] [Related]

  • 8. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.
    Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D.
    Arch Intern Med; 2000 Feb 28; 160(4):517-25. PubMed ID: 10695692
    [Abstract] [Full Text] [Related]

  • 9. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
    Hosking D, Adami S, Felsenberg D, Andia JC, Välimäki M, Benhamou L, Reginster JY, Yacik C, Rybak-Feglin A, Petruschke RA, Zaru L, Santora AC.
    Curr Med Res Opin; 2003 Feb 28; 19(5):383-94. PubMed ID: 13678475
    [Abstract] [Full Text] [Related]

  • 10. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study.
    Greenspan S, Field-Munves E, Tonino R, Smith M, Petruschke R, Wang L, Yates J, de Papp AE, Palmisano J.
    Mayo Clin Proc; 2002 Oct 28; 77(10):1044-52. PubMed ID: 12374248
    [Abstract] [Full Text] [Related]

  • 11. Upper gastrointestinal safety and tolerability of oral alendronate: A meta-analysis.
    Zhou M, Zheng Y, Li J, Wu J, Xu W, Cui L, Yao W, Liu Y.
    Exp Ther Med; 2016 Jan 28; 11(1):289-296. PubMed ID: 26889256
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ.
    Aging (Milano); 2000 Feb 28; 12(1):1-12. PubMed ID: 10746426
    [Abstract] [Full Text] [Related]

  • 13. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG.
    Clin Ther; 2008 Apr 28; 30(4):605-21. PubMed ID: 18498910
    [Abstract] [Full Text] [Related]

  • 14. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 28; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 15. The clinical tolerability profile of alendronate.
    Watts N, Freedholm D, Daifotis A.
    Int J Clin Pract Suppl; 1999 Apr 28; 101():51-61. PubMed ID: 12669741
    [Abstract] [Full Text] [Related]

  • 16. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study.
    Eisman JA, Rizzoli R, Roman-Ivorra J, Lipschitz S, Verbruggen N, Gaines KA, Melton ME.
    Curr Med Res Opin; 2004 May 28; 20(5):699-705. PubMed ID: 15140336
    [Abstract] [Full Text] [Related]

  • 17. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
    Recker R, Lips P, Felsenberg D, Lippuner K, Benhamou L, Hawkins F, Delmas PD, Rosen C, Emkey R, Salzmann G, He W, Santora AC.
    Curr Med Res Opin; 2006 Sep 28; 22(9):1745-55. PubMed ID: 16968578
    [Abstract] [Full Text] [Related]

  • 18. Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis.
    Luckey M, Kagan R, Greenspan S, Bone H, Kiel RD, Simon J, Sackarowitz J, Palmisano J, Chen E, Petruschke RA, de Papp AE.
    Menopause; 2004 Sep 28; 11(4):405-15. PubMed ID: 15243278
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation.
    Bone HG, Walter MA, Hurley ME, Epstein S.
    Osteoporos Int; 2017 May 28; 28(5):1745-1752. PubMed ID: 28204953
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.